Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 1.95
OCRX's Cash-to-Debt is ranked lower than
68% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. OCRX: 1.95 )
Ranked among companies with meaningful Cash-to-Debt only.
OCRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.67  Med: 3.73 Max: No Debt
Current: 1.95
Debt-to-Equity 1.92
OCRX's Debt-to-Equity is ranked lower than
82% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. OCRX: 1.92 )
Ranked among companies with meaningful Debt-to-Equity only.
OCRX' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.26  Med: 0.38 Max: 1.92
Current: 1.92
-2.26
1.92
Debt-to-EBITDA -0.32
OCRX's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. OCRX: -0.32 )
Ranked among companies with meaningful Debt-to-EBITDA only.
OCRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.49  Med: -0.54 Max: -0.32
Current: -0.32
-2.49
-0.32
Piotroski F-Score: 3
Altman Z-Score: -18.20
Beneish M-Score: -0.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -4238.18
OCRX's Operating Margin % is ranked lower than
88% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. OCRX: -4238.18 )
Ranked among companies with meaningful Operating Margin % only.
OCRX' s Operating Margin % Range Over the Past 10 Years
Min: -19801.5  Med: -5209.25 Max: -63.42
Current: -4238.18
-19801.5
-63.42
Net Margin % -4406.91
OCRX's Net Margin % is ranked lower than
88% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. OCRX: -4406.91 )
Ranked among companies with meaningful Net Margin % only.
OCRX' s Net Margin % Range Over the Past 10 Years
Min: -20604.71  Med: -5263.59 Max: -85.5
Current: -4406.91
-20604.71
-85.5
ROE % -197.96
OCRX's ROE % is ranked lower than
86% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. OCRX: -197.96 )
Ranked among companies with meaningful ROE % only.
OCRX' s ROE % Range Over the Past 10 Years
Min: -236.08  Med: -89.59 Max: -49.17
Current: -197.96
-236.08
-49.17
ROA % -95.10
OCRX's ROA % is ranked lower than
81% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. OCRX: -95.10 )
Ranked among companies with meaningful ROA % only.
OCRX' s ROA % Range Over the Past 10 Years
Min: -230.64  Med: -64.59 Max: -15.31
Current: -95.1
-230.64
-15.31
ROC (Joel Greenblatt) % -44576.92
OCRX's ROC (Joel Greenblatt) % is ranked lower than
94% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. OCRX: -44576.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OCRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -46351.52  Med: -4243.35 Max: -526.49
Current: -44576.92
-46351.52
-526.49
3-Year Revenue Growth Rate 26.00
OCRX's 3-Year Revenue Growth Rate is ranked higher than
78% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. OCRX: 26.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OCRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -48.65 Max: 26
Current: 26
0
26
3-Year EBITDA Growth Rate -21.60
OCRX's 3-Year EBITDA Growth Rate is ranked lower than
77% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. OCRX: -21.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OCRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -67.65 Max: -21.6
Current: -21.6
3-Year EPS without NRI Growth Rate -21.50
OCRX's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. OCRX: -21.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OCRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -69.15 Max: -21.5
Current: -21.5
GuruFocus has detected 4 Warning Signs with Ocera Therapeutics Inc OCRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OCRX's 30-Y Financials

Financials (Next Earnings Date: 2018-03-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

OCRX Guru Trades in Q2 2016

Jim Simons 169,100 sh (+15.51%)
» More
Q3 2016

OCRX Guru Trades in Q3 2016

Jim Simons 185,800 sh (+9.88%)
» More
Q4 2016

OCRX Guru Trades in Q4 2016

Jim Simons 219,100 sh (+17.92%)
» More
Q1 2017

OCRX Guru Trades in Q1 2017

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XTAE:CFBI, ASX:FTT, NAS:VICL, ASX:PBT, ASX:OCC, XKRX:066830, NAS:NVUS, NAS:ZSAN, NAS:EBIO, TSXV:IPA, NAS:ONCS, XPAR:ALPAT, OSTO:BIOVIC B, OSTO:GENO, XKRX:127120, XKRX:228180, NAS:CERC, NAS:PTIE, XCNQ:MYM, FRA:ELN » details
Traded in other countries:6TY1.Germany,
Headquarter Location:USA
Ocera Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of proprietary compounds to treat acute and chronic orphan liver disease.

Ocera Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of proprietary compounds to treat acute and chronic orphan liver disease.

Top Ranked Articles about Ocera Therapeutics Inc

Lifshitz & Miller LLP Announces Investigation of Manitex International, Inc., Novan, Inc., Ocera Therapeutics, Inc., Planet Payment, Inc., RE/MAX Holdings, Inc., Super Micro Computer, Inc. and World Acceptance Corporation
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Ocera Therapeutics, Inc. - OCRX
Mallinckrodt To Acquire Ocera Therapeutics And OCR-002, Its Proprietary Therapy In Development For Treatment Of Hepatic Encephalopathy
Mallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy
Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017
Ocera Therapeutics Reports Second Quarter 2017 Financial Results
Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis
Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2
Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update
Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017

Ratios

vs
industry
vs
history
PB Ratio 11.86
OCRX's PB Ratio is ranked higher than
60% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. OCRX: 11.86 )
Ranked among companies with meaningful PB Ratio only.
OCRX' s PB Ratio Range Over the Past 10 Years
Min: 0.88  Med: 2.52 Max: 12.21
Current: 11.86
0.88
12.21
PS Ratio 78.19
OCRX's PS Ratio is ranked lower than
75% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. OCRX: 78.19 )
Ranked among companies with meaningful PS Ratio only.
OCRX' s PS Ratio Range Over the Past 10 Years
Min: 0.06  Med: 83.33 Max: 3600
Current: 78.19
0.06
3600
EV-to-EBIT -1.67
OCRX's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. OCRX: -1.67 )
Ranked among companies with meaningful EV-to-EBIT only.
OCRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.2  Med: -1.5 Max: 1.1
Current: -1.67
-19.2
1.1
EV-to-EBITDA -1.67
OCRX's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. OCRX: -1.67 )
Ranked among companies with meaningful EV-to-EBITDA only.
OCRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.4  Med: -1.6 Max: 1.1
Current: -1.67
-19.4
1.1
EV-to-Revenue 70.21
OCRX's EV-to-Revenue is ranked lower than
66% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. OCRX: 70.21 )
Ranked among companies with meaningful EV-to-Revenue only.
OCRX' s EV-to-Revenue Range Over the Past 10 Years
Min: -8.1  Med: 74.9 Max: 2839.2
Current: 70.21
-8.1
2839.2
Current Ratio 1.27
OCRX's Current Ratio is ranked lower than
79% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. OCRX: 1.27 )
Ranked among companies with meaningful Current Ratio only.
OCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.62  Med: 4.57 Max: 21.99
Current: 1.27
0.62
21.99
Quick Ratio 1.27
OCRX's Quick Ratio is ranked lower than
75% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. OCRX: 1.27 )
Ranked among companies with meaningful Quick Ratio only.
OCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 4.57 Max: 21.99
Current: 1.27
0.62
21.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.50
OCRX's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. OCRX: -15.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OCRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -984.4  Med: -61.75 Max: 0
Current: -15.5
-984.4
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 17.20
OCRX's Price-to-Net-Cash is ranked higher than
76% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. OCRX: 17.20 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OCRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.54  Med: 3.1 Max: 17.4
Current: 17.2
1.54
17.4
Price-to-Net-Current-Asset-Value 14.33
OCRX's Price-to-Net-Current-Asset-Value is ranked higher than
77% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. OCRX: 14.33 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OCRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.35  Med: 2.8 Max: 14.5
Current: 14.33
1.35
14.5
Price-to-Tangible-Book 14.33
OCRX's Price-to-Tangible-Book is ranked higher than
66% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. OCRX: 14.33 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OCRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.24  Med: 2.69 Max: 14.5
Current: 14.33
1.24
14.5
Price-to-Median-PS-Value 0.94
OCRX's Price-to-Median-PS-Value is ranked higher than
91% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. OCRX: 0.94 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OCRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 3.04 Max: 33.88
Current: 0.94
0.03
33.88
Earnings Yield (Greenblatt) % -60.00
OCRX's Earnings Yield (Greenblatt) % is ranked lower than
95% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. OCRX: -60.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OCRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -315.3  Med: -48.8 Max: 1821
Current: -60
-315.3
1821

More Statistics

Revenue (TTM) (Mil) $0.55
EPS (TTM) $ -0.96
Beta1.10
Short Percentage of Float2.09%
52-Week Range $0.52 - 2.95
Shares Outstanding (Mil)26.51

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $)
EPS ($) -0.93 -0.95 -1.01 -0.80
EPS without NRI ($) -0.93 -0.95 -1.01 -0.80
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}